Join
Live feed
·
PRReleasevia Quantisnow
Gyre Therapeutics Inc. logo

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

ByQuantisnow·Wall Street's wire, on your screen.
GYRE· Gyre Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GYRE (Gyre Therapeutics Inc.) and more on Quantisnow.